NLBNPIT1VQS5 20991231 58.8506 (P1VQS5) News

Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Late-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher disease Poster...

Form EFFECT - Notice of Effectiveness

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form POS AM - Post-Effective amendments for registration statement

Form SC 13E3/A - Going private transaction by certain issuers: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Acquisition of Freeline by Syncona Becomes Effective

LONDON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (“Freeline”) and...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Freeline Shareholders Approve Acquisition by Syncona

LONDON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (“Freeline”) and...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SC 13E3/A - Going private transaction by certain issuers: [Amend]

Form SC 13E3 - Going private transaction by certain issuers